Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Tips offered in April 2010 issue of American Journal Of Pathology

A group led by Dr. Massimo Loda at the Dana Farber Cancer Institute, Boston, MA has generated a preclinical model of human prostate cancer that mimics the genetic and growth behavior of primary tumors. Their report can be found in the April 2010 issue of the American Journal of Pathology.

25 Mar 2010

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent

Techulon Inc., a life sciences company, has signed worldwide exclusive license agreements with the University of Cincinnati to manufacture and sell novel transfection reagents used for research and therapeutic delivery of nucleic acids.

25 Mar 2010

BeaconEquity.com announces investment report on AEterna Zentaris

BeaconEquity.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

25 Mar 2010

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has earned a $20 million technology transfer payment from Takeda Pharmaceutical Company Limited as part of the strategic alliance the companies formed in May 2008.

23 Mar 2010

Panel: Management of ocean to enhance human health and reduce public health risks

On Monday, March 22, NOAA's Oceans and Human Health Initiative will host two briefings to key House and Senate staffers on NOAA's efforts to improve understanding and management of the ocean, coasts, and Great Lakes to enhance benefits to human health and reduce public health risks.

20 Mar 2010

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

A collaborative project between Sanford-Burnham Medical Research Institute at Lake Nona and Analiza, Inc. has yielded aqueous solubility data for over 20,000 compounds in the NIH Molecular Library within the first 90 days of screening and characterization.

19 Mar 2010

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

The University of Pennsylvania and AstraZeneca today announced a new collaborative research agreement to make use of their respective talents and resources in an effort to bridge the transition from drug discovery to development.

19 Mar 2010

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE™ technology for delivery of genes into cells.

18 Mar 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.

18 Mar 2010

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

The ALS Therapy Development Institute and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

17 Mar 2010

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

Ingenuity Systems, the leading provider of information solutions for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece, Turkey and the Balkan countries. IPA is the leading software application to model, analyze, and understand the complex biological and chemical systems at the core of life science research.

17 Mar 2010

Human amniotic fluid skin cells "reprogrammed" to pluripotency

In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.

16 Mar 2010

Kinexus Bioinformatics launches new peptide synthesis facility

Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced the launch of a new peptide synthesis facility to provide researchers with the latest in peptide array technologies. These new services will facilitate and expedite access to peptide platforms for innovative approaches to proteomic research and discovery.

16 Mar 2010

Houston scientists unveil new technique for growing 3-D cell cultures

The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.

16 Mar 2010

CytRx plans five Phase 2 clinical trials with oncology drug candidates

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the twelve months ended December 31, 2009, and affirmed its 2010 milestones of commencing up to five Phase 2 clinical trials with its oncology drug candidates.

15 Mar 2010

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

Caliper Life Sciences enters into settlement agreement with Shimadzu and its subsidiary Shimadzu Scientific Instruments

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announces that it has entered into a settlement agreement with Shimadzu Corporation and its wholly owned subsidiary Shimadzu Scientific Instruments, Inc., resolving a lawsuit filed by Caliper in the United States District Court for the Eastern District of Texas that claimed that Shimadzu's MultiNA microchip-based electrophoresis system infringed several U.S. patents relating to Caliper's microfluidic LabChip® technology.

15 Mar 2010

Two controlled environmental variables to preclinical mice tests can reduce costly false positives: Study

For decades, the traditional practice in animal testing has been standardization, but a study involving Purdue University has shown that adding as few as two controlled environmental variables to preclinical mice tests can greatly reduce costly false positives, the number of animals needed for testing and the cost of pharmaceutical trials.

15 Mar 2010

Drug Discovery News and Research

Further Reading

Tips offered in April 2010 issue of American Journal Of Pathology

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent

BeaconEquity.com announces investment report on AEterna Zentaris

Evotec AG reports financial results and corporate updates for 2009

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Panel: Management of ocean to enhance human health and reduce public health risks

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

Human amniotic fluid skin cells "reprogrammed" to pluripotency

Kinexus Bioinformatics launches new peptide synthesis facility

Houston scientists unveil new technique for growing 3-D cell cultures

CytRx plans five Phase 2 clinical trials with oncology drug candidates

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

Caliper Life Sciences enters into settlement agreement with Shimadzu and its subsidiary Shimadzu Scientific Instruments

Two controlled environmental variables to preclinical mice tests can reduce costly false positives: Study

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News